Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with cancer, according to a press Read more…
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent use after surgery, according to Read more…
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Doll, M.D., from the University Read more…
For children with high-risk group 3 medulloblastoma, therapy intensification with carboplatin improves event-free survival, according to a study published online July 22 in JAMA Oncology. Sarah E. S. Leary, M.D., from Seattle Children’s, and colleagues examined therapy intensification with carboplatin as Read more…
For adolescents and young adults (AYAs) with cancer, living in rural counties and living farther from the reporting hospital are associated with later-stage diagnoses and increased mortality, according to a study published online July 8 in Cancer. Kimberly J. Johnson, M.P.H., Read more…
Flatiron Health real-world data (RWD) supported the U.S. Food and Drug Administration (FDA)’s recent approval of a new dosing regimen for ERBITUX® (Eli Lilly and Company’s cetuximab) that can have a direct positive impact on the lives of patients with metastatic Read more…
A new study, led by the University of Glasgow and published in The Lancet, has compared the three main ways anticancer treatment is given to patients when administered via a central vein. Hickman-type tunnelled catheters (Hickman), peripherally inserted central catheters Read more…
People with heart failure may live for many years and should continue to get regular cancer screenings, experts say. People with heart failure may be at increased risk for cancer. Cancer patients are usually monitored for heart failure because some Read more…
The US Food and Drug Administration (FDA) on Wednesday released draft guidance to help sponsors establish the effectiveness and safety of gonadotropin-releasing hormone (GnRH) analogues for treating advanced prostate cancer.GnRH agonists and antagonists are a mainstay for treating patients with Read more…
Pancreatic cancer often kills people because they are diagnosed too late, after their tumors have spread. Other patients may die following the removal of harmless cysts that appear threatening amid a fog of imaging data and other clinical information. But Read more…